MARKET

SMMT

SMMT

Summit Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.71
-0.25
-4.19%
Pre Market: 5.16 -0.55 -9.63% 07:24 03/05 EST
OPEN
5.97
PREV CLOSE
5.96
HIGH
6.04
LOW
5.36
VOLUME
1
TURNOVER
--
52 WEEK HIGH
12.30
52 WEEK LOW
1.420
MARKET CAP
471.50M
P/E (TTM)
7.12
1D
5D
1M
3M
1Y
5Y
Tin Electroplating Market Size, Growth and Forecast 2020 to 2027 By Ameco Research
pune, India, Tue, 02 Mar 2021 02:44:47 / Comserve Inc. / -- The global Tin Electroplating market is segmented by company, region (country), by Type, and by...
Comserve · 3d ago
DJ Summit Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since June 2018 -- Data Talk
Dow Jones · 02/09 16:35
KalVista Pharmaceuticals, Heat Biologics leads healthcare gainers; Aeterna Zentaris, Ekso Bionics among major losers
Gainers: KalVista Pharmaceuticals KALV +134%, Heat Biologics HTBX +70%, Iterum Therapeutics (ITRM) +48%, OrganiGram OGI +47%, Oragenics (OGEN) +24%.Losers: Aeterna Zentaris (AEZS) -27%, Ekso Bionics EKSO -23%, Ocugen OCGN -23%, Hancock Jaffe Laboratories (...
Seekingalpha · 02/09 16:02
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 9)
Benzinga · 02/09 13:10
The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 4)
Benzinga · 02/05 12:44
The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26)
Benzinga · 01/27 12:35
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)
Benzinga · 12/23/2020 13:29
The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 17)
Benzinga · 12/18/2020 12:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SMMT. Analyze the recent business situations of Summit Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SMMT stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 14.34M
% Owned: 17.37%
Shares Outstanding: 82.58M
TypeInstitutionsShares
Increased
4
63.92K
New
27
7.37M
Decreased
4
1.13M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.62%
Pharmaceuticals & Medical Research
-2.13%
Key Executives
Chief Operating Officer
Mahkam Zanganeh
Chief Executive Officer/Executive Director
Glyn Edwards
Chief Operating Officer/Executive Director
Elaine Stracker
Chief Financial Officer
Erik Ostrowski
Non-Executive Independent Director
Rainer Erdtmann
Chief Operating Officer
David Roblin
Other
Ralf Rosskamp
Non-Executive Director
Valerie Andrews
Non-Executive Director
Barry Price
Non-Executive Director
David Wurzer
No Data
About SMMT
Summit Therapeutics Inc. is focused on developing treatments for infectious diseases. The Company uses its Discuva platform, an antibiotic discovery engine to develop antibiotics. It is initially focused on Clostridioides difficile infections (CDI). Its platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. Ridinilazole is its new mechanism antibiotic, which is being developed for CDI.

Webull offers kinds of Summit Therapeutics Inc stock information, including NASDAQ:SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.